34 results on '"Roblin X."'
Search Results
2. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort
3. Letter: thiopurines ‐ is less really more? Authors’ reply
4. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authorsʼ reply
5. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
6. Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease
7. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal
8. Letter: stool adalimumab detection in ulcerative colitis and Crohnʼs disease
9. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease
10. The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease
11. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases
12. Letter: extracorporeal photopheresis in refractory chronic active ulcerative colitis
13. Letter: mucosal healing in ulcerative colitis – higher relevance than in Crohnʼs disease? Authorsʼ reply
14. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience
15. Letter: TPMT activity and age in IBD patients – authorsʼ reply
16. Letter: thiopurine blood monitoring for patients with inflammatory bowel disease – authorsʼ reply
17. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease
18. Appendicectomy as a potential therapy for refractory ulcerative proctitis
19. The use of azathioprine in Crohnʼs disease during pregnancy and in the post-operative setting: a worldwide survey of experts
20. Infliximab for refractory ulcerative proctitis
21. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey
22. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience
23. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression
24. Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohnʼs disease
25. 6-Tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine
26. Drug interaction between infliximab and azathioprine in patients with Crohnʼs disease
27. Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients
28. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor
29. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study
30. Letter: thiopurines - is less really more? Authors’ reply
31. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial
32. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
33. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
34. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.